Long-term outcomes in patients with symptomatic coronary art
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
In patients with asymptomatic moderate to severe aortic stenosis (AS), serum biomarkers that predict outcome might allow individualized monitoring and optimization of the timing of intervention. Researchers measured several known and novel biomarkers in 173 asymptomatic patients (mean age 69 years, 55% male) with at least moderate AS, defined as an aortic velocity of 3 m/s or higher or a valve area of 1.2 cm2 or less, and normal left ventricular systolic function (ejection fraction 50% or higher). The primary combined outcome (all-cause mortality, heart failure hospitalization, or progression to NYHA classes III-IV) occurred in 34% at a median follow-up of 2.7 (1.4–4.6) years. Of the six biomarkers measured, mid-regional pro adrenomedullin (MR-proADM) had the highest discriminative value for the primary endpoint (subdistribution HR (SHR) 11.3, 95% CI 3.9 to 32.7).

Source: https://heart.bmj.com/content/108/16/1247